FBRSL1

Summary

FBRSL1 (fibrosin like 1, HGNC:29308) is a protein-coding gene on chromosome 12q24.33, encoding Fibrosin-1-like protein (Q9HCM7).

Enables RNA binding activity.

Source: NCBI Gene 57666 — RefSeq curated summary.

At a glance

• Gene–disease (curated): syndromic disease (Strong, GenCC) — +2 more curated relationships
• GWAS associations: 22
• Clinical variants (ClinVar): 417 total — 1 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_001367871

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29308
Approved symbol	FBRSL1
Name	fibrosin like 1
Location	12q24.33
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1545
Ensembl gene	ENSG00000112787
Ensembl biotype	protein_coding
OMIM	620123
Entrez	57666

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 21 protein_coding, 4 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000434748, ENST00000537804, ENST00000539264, ENST00000542061, ENST00000542306, ENST00000543360, ENST00000543453, ENST00000650108, ENST00000680143, ENST00000938321, ENST00000938322, ENST00000938323, ENST00000938324, ENST00000938325, ENST00000938326, ENST00000938327, ENST00000955040, ENST00000955041, ENST00000955042, ENST00000955043, ENST00000955044, ENST00000955045, ENST00000955046, ENST00000955047, ENST00000955048, ENST00000955049

RefSeq mRNA: 6 — MANE Select: NM_001367871 NM_001142641, NM_001367871, NM_001382739, NM_001382740, NM_001382741, NM_001382742

CCDS: CCDS45010, CCDS91782, CCDS91783

Canonical transcript exons

ENST00000680143 — 19 exons

Exon	Start	End
ENSE00000759745	132582062	132582266
ENSE00000798053	132570335	132570540
ENSE00001683027	132548003	132548032
ENSE00001705919	132569926	132570241
ENSE00001707018	132525734	132525823
ENSE00001710027	132582971	132585188
ENSE00001781255	132508153	132508350
ENSE00001788931	132527953	132527988
ENSE00002210068	132574090	132574158
ENSE00003458280	132576799	132576931
ENSE00003479296	132581741	132581824
ENSE00003488918	132572527	132572622
ENSE00003567068	132581439	132581516
ENSE00003644199	132572288	132572344
ENSE00003663950	132567481	132567526
ENSE00003833061	132574493	132574564
ENSE00003833796	132574319	132574348
ENSE00003910871	132571068	132571231
ENSE00003913221	132490151	132490861

Expression profiles

Bgee: expression breadth ubiquitous, 248 present calls, max score 98.80.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 44.1191 / max 464.9567, expressed in 1817 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
128816	28.5272	1809
128820	10.3397	1334
128821	3.2023	993
128822	1.4953	741
128815	0.2401	103
128818	0.1367	58
128823	0.0835	12
128817	0.0557	15
128819	0.0386	7

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	98.80	gold quality
oviduct epithelium	UBERON:0004804	98.33	gold quality
cortical plate	UBERON:0005343	97.07	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.94	gold quality
cerebellar cortex	UBERON:0002129	96.37	gold quality
body of pancreas	UBERON:0001150	96.35	gold quality
cerebellar hemisphere	UBERON:0002245	96.35	gold quality
apex of heart	UBERON:0002098	96.19	gold quality
cerebellum	UBERON:0002037	95.89	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.88	gold quality
adenohypophysis	UBERON:0002196	95.86	gold quality
right uterine tube	UBERON:0001302	95.81	gold quality
granulocyte	CL:0000094	95.65	gold quality
sural nerve	UBERON:0015488	95.54	gold quality
small intestine Peyer’s patch	UBERON:0003454	95.21	gold quality
pituitary gland	UBERON:0000007	94.90	gold quality
body of stomach	UBERON:0001161	94.90	gold quality
metanephros cortex	UBERON:0010533	94.83	gold quality
lower esophagus muscularis layer	UBERON:0035833	94.73	gold quality
lower esophagus	UBERON:0013473	94.71	gold quality
right ovary	UBERON:0002118	94.57	gold quality
gastrocnemius	UBERON:0001388	94.56	gold quality
left uterine tube	UBERON:0001303	94.51	gold quality
right testis	UBERON:0004534	94.48	gold quality
left testis	UBERON:0004533	94.47	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	94.45	gold quality
muscle layer of sigmoid colon	UBERON:0035805	94.29	gold quality
body of uterus	UBERON:0009853	94.28	gold quality
left ovary	UBERON:0002119	94.25	gold quality
transverse colon	UBERON:0001157	94.22	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.71
E-ENAD-17	no	3.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

77 targeting FBRSL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-6715A-3P	99.83	68.05	1473
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-636	99.80	69.58	1500
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085

Literature-anchored findings (GeneRIF, showing 2)

• Association analysis and polygenic risk score evaluation of 38 GWAS-identified Loci in a Chinese population with Parkinson’s disease. (PMID:34352340)
• Fbrsl1 is required for heart development in Xenopus laevis and de novo variants in FBRSL1 can cause human heart defects. (PMID:38501224)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	fbrsl1	ENSDARG00000058232
mus_musculus	Fbrsl1	ENSMUSG00000043323
rattus_norvegicus	Fbrsl1	ENSRNOG00000030721

Paralogs (2): FBRS (ENSG00000156860), AUTS2 (ENSG00000158321)

Protein

Protein identifiers

Fibrosin-1-like protein — Q9HCM7 (reviewed: Q9HCM7)

Alternative names: AUTS2-like protein, HBV X-transactivated gene 9 protein, HBV XAg-transactivated protein 9

All UniProt accessions (4): A0A1B0GUN3, A0A3B3IRR3, A0A7P0Z485, Q9HCM7

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the AUTS2 family.

RefSeq proteins (6): NP_001136113, NP_001354800, NP_001369668, NP_001369669, NP_001369670, NP_001369671 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR023246	AUTS2	Family

Pfam: PF15336

UniProt features (30 total): compositionally biased region 13, region of interest 7, modified residue 6, chain 1, cross-link 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HCM7-F1	46.19	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 340, 790, 937, 977, 989, 1010, 858

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (0):

GO Molecular Function (1): RNA binding (GO:0003723)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nucleic acid binding	1

Protein interactions and networks

STRING

916 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FBRSL1	PCGF5	Q86SE9	610
FBRSL1	PCGF3	Q3KNV8	573
FBRSL1	OR4N5	Q8IXE1	492
FBRSL1	BTBD17	A6NE02	410
FBRSL1	DNAAF8	Q8IYS4	370
FBRSL1	MTHFSD	Q2M296	364
FBRSL1	FAM184B	Q9ULE4	363
FBRSL1	MTX3	Q5HYI7	357
FBRSL1	SPATC1L	Q9H0A9	352
FBRSL1	POMZP3	Q6PJE2	350
FBRSL1	HDGFL2	Q7Z4V5	344
FBRSL1	YAF2	Q8IY57	334
FBRSL1	OC90	Q02509	329
FBRSL1	LRRC75A	Q8NAA5	329
FBRSL1	OR5A2	Q8NGI9	324

IntAct

62 interactions, top by confidence:

A	B	Type	Score
RYBP	BMI1	psi-mi:“MI:0914”(association)	0.850
CSNK2A1	EIF3J	psi-mi:“MI:0914”(association)	0.810
CSNK2A2	EIF3J	psi-mi:“MI:0914”(association)	0.790
RYBP	E2F6	psi-mi:“MI:0914”(association)	0.740
DCAF7	DIAPH1	psi-mi:“MI:0914”(association)	0.730
RING1	CBX4	psi-mi:“MI:0914”(association)	0.730
NFIC	NFIB	psi-mi:“MI:2364”(proximity)	0.690
CSNK2B	NMT2	psi-mi:“MI:0914”(association)	0.660
RNF2	CBX4	psi-mi:“MI:0914”(association)	0.660
YAF2	E2F6	psi-mi:“MI:0914”(association)	0.640
CSNK2B	RPS6KA4	psi-mi:“MI:0914”(association)	0.640
CSNK2A2	PES1	psi-mi:“MI:0914”(association)	0.640
CSNK2A1	SURF6	psi-mi:“MI:0914”(association)	0.590
DCAF7	PFDN6	psi-mi:“MI:2364”(proximity)	0.570
DCAF7	PFDN6	psi-mi:“MI:0914”(association)	0.570
FANCD2OS	CNOT1	psi-mi:“MI:0914”(association)	0.530
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
DCAF7	DIAPH1	psi-mi:“MI:0914”(association)	0.350
CSNK2A1	EIF3F	psi-mi:“MI:0914”(association)	0.350
DCAF7	SOWAHB	psi-mi:“MI:0914”(association)	0.350
RYBP	MGAM	psi-mi:“MI:0914”(association)	0.350

BioGRID (90): FBRSL1 (Affinity Capture-MS), FBRSL1 (Affinity Capture-MS), FBRSL1 (Affinity Capture-MS), FBRSL1 (Affinity Capture-MS), FBRSL1 (Affinity Capture-MS), FBRSL1 (Affinity Capture-MS), FBRSL1 (Affinity Capture-MS), FBRSL1 (Affinity Capture-MS), FBRSL1 (Affinity Capture-RNA), FBRSL1 (Affinity Capture-RNA), FBRSL1 (Affinity Capture-MS), FBRSL1 (Affinity Capture-MS), FBRSL1 (Affinity Capture-MS), FBRSL1 (Affinity Capture-MS), FBRSL1 (Affinity Capture-MS)

ESM2 similar proteins: A0A087WPF7, A0A0R4IBL7, O09000, O54972, O70305, O75081, O75376, P15806, P15881, P15884, P15923, P21677, P30985, P51514, P98180, Q05AQ8, Q14157, Q14687, Q1LY51, Q2VPM4, Q3U3C9, Q4KKX4, Q4VCS5, Q566L4, Q5F3B1, Q5SFM8, Q5T6F2, Q60722, Q60974, Q61286, Q62655, Q6DIH5, Q7ZWN6, Q7ZXS3, Q80X50, Q86YP4, Q8BZ47, Q8CHY6, Q8IXK0, Q8VHG2

Diamond homologs: A0A087WPF7, Q8R089, Q8WXX7, Q9HAH7, Q9HCM7

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 68 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	10	65.3×	3e-14
Transcriptional Regulation by E2F6	7	44.6×	1e-08
SUMOylation of transcription cofactors	5	26.4×	4e-05
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	5	15.9×	3e-04

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	5	30.4×	5e-05
inner ear morphogenesis	5	22.8×	2e-04
anatomical structure morphogenesis	7	14.8×	5e-05
chromatin remodeling	9	9.9×	4e-05
transcription by RNA polymerase II	8	8.6×	2e-04
gene expression	6	7.3×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

417 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	304
Likely benign	61
Benign	7

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
2684684	GRCh37/hg19 12q24.31-24.33(chr12:120880079-133777902)x3	Pathogenic
982214	NM_001367871.1(FBRSL1):c.1522C>G (p.Gln508Glu)	Likely pathogenic

SpliceAI

4632 predictions. Top by Δscore:

Variant	Effect	Δscore
12:132508148:T:TA	acceptor_gain	1.0000
12:132508151:A:AG	acceptor_gain	1.0000
12:132508151:AGAAG:A	acceptor_gain	1.0000
12:132508152:G:GT	acceptor_gain	1.0000
12:132508152:GA:G	acceptor_gain	1.0000
12:132508152:GAA:G	acceptor_gain	1.0000
12:132508152:GAAGG:G	acceptor_gain	1.0000
12:132508347:GCAG:G	donor_gain	1.0000
12:132508348:CAG:C	donor_loss	1.0000
12:132508349:AG:A	donor_loss	1.0000
12:132508350:GG:G	donor_loss	1.0000
12:132508352:T:G	donor_loss	1.0000
12:132525732:A:AG	acceptor_gain	1.0000
12:132525732:AGAT:A	acceptor_gain	1.0000
12:132525733:G:GA	acceptor_gain	1.0000
12:132525733:GAT:G	acceptor_gain	1.0000
12:132525733:GATG:G	acceptor_gain	1.0000
12:132525733:GATGA:G	acceptor_gain	1.0000
12:132525819:GCGAT:G	donor_gain	1.0000
12:132525820:CGAT:C	donor_gain	1.0000
12:132525821:GAT:G	donor_gain	1.0000
12:132525821:GATG:G	donor_gain	1.0000
12:132525822:AT:A	donor_gain	1.0000
12:132525823:TGT:T	donor_loss	1.0000
12:132525824:G:GG	donor_gain	1.0000
12:132525824:GTGA:G	donor_loss	1.0000
12:132525825:T:G	donor_loss	1.0000
12:132527989:G:GG	donor_gain	1.0000
12:132548001:A:AG	acceptor_gain	1.0000
12:132548002:G:GG	acceptor_gain	1.0000

AlphaMissense

6381 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:132490824:T:C	F85S	1.000
12:132490823:T:C	F85L	0.999
12:132490825:C:A	F85L	0.999
12:132490825:C:G	F85L	0.999
12:132490815:T:A	I82N	0.998
12:132490830:T:A	I87N	0.998
12:132490838:T:C	F90L	0.998
12:132490840:C:A	F90L	0.998
12:132490840:C:G	F90L	0.998
12:132490853:G:C	A95P	0.998
12:132490818:A:T	D83V	0.997
12:132490824:T:G	F85C	0.997
12:132490857:T:C	L96P	0.997
12:132572611:T:C	F525L	0.997
12:132572613:T:A	F525L	0.997
12:132572613:T:G	F525L	0.997
12:132490815:T:G	I82S	0.996
12:132490835:A:C	S89R	0.996
12:132490837:C:A	S89R	0.996
12:132490837:C:G	S89R	0.996
12:132490839:T:C	F90S	0.996
12:132574505:T:A	W591R	0.996
12:132574505:T:C	W591R	0.996
12:132574510:T:G	C592W	0.996
12:132574507:G:C	W591C	0.995
12:132574507:G:T	W591C	0.995
12:132490821:G:A	G84D	0.994
12:132490827:C:A	A86D	0.994
12:132572612:T:C	F525S	0.994
12:132572612:T:G	F525C	0.994

dbSNP variants (sampled 300 via entrez): RS1000001599 (12:132495415 T>C), RS1000017391 (12:132558163 C>T), RS1000023145 (12:132528799 C>T), RS1000039147 (12:132564708 G>A,C), RS1000042865 (12:132585418 C>T), RS1000089057 (12:132557978 G>A), RS1000158483 (12:132527236 G>A,T), RS1000173350 (12:132541245 A>G), RS1000210856 (12:132539171 T>C), RS1000212664 (12:132533332 C>A,T), RS1000218393 (12:132562343 A>C), RS1000242230 (12:132533576 C>T), RS1000254489 (12:132510696 G>A,C), RS1000288568 (12:132514568 C>T), RS1000294313 (12:132553089 C>G)

Disease associations

OMIM: gene MIM:620123 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
syndromic disease	Strong	Autosomal dominant
complex neurodevelopmental disorder	Moderate	Autosomal dominant
syndromic complex neurodevelopmental disorder	Moderate	Autosomal dominant

Mondo (3): syndromic disease (MONDO:0002254), complex neurodevelopmental disorder (MONDO:0100038), syndromic complex neurodevelopmental disorder (MONDO:0800439)

Orphanet (1): Moyamoya angiopathy (Orphanet:477768)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

22 associations (top):

Study	Trait	p-value
GCST004601_168	Red blood cell count	6.000000e-14
GCST005951_3	Body mass index	6.000000e-09
GCST006085_58	Prostate cancer	1.000000e-09
GCST006089_11	Prostate cancer (early onset)	6.000000e-08
GCST006414_16	Atrial fibrillation	1.000000e-08
GCST006628_35	Systolic blood pressure	3.000000e-10
GCST007545_2	Coronary artery disease and triglyceride levels (multivariate analysis)	1.000000e-08
GCST008839_158	Height	2.000000e-09
GCST008971_3	Urate levels	2.000000e-13
GCST008972_80	Urate levels	1.000000e-14
GCST009325_12	Parkinson’s disease or first degree relation to individual with Parkinson’s disease	2.000000e-10
GCST009379_354	Type 2 diabetes	2.000000e-12
GCST009870_11	Calcific aortic valve stenosis	2.000000e-06
GCST010204_163	Low density lipoprotein cholesterol levels	5.000000e-09
GCST010241_390	Apolipoprotein A1 levels	8.000000e-10
GCST011956_141	Systemic lupus erythematosus	6.000000e-09
GCST012490_190	Femur bone mineral density x serum urate levels interaction	4.000000e-08
GCST012490_557	Femur bone mineral density x serum urate levels interaction	8.000000e-12
GCST90002383_19	Hematocrit	1.000000e-13
GCST90002384_322	Hemoglobin	4.000000e-15
GCST90002392_402	Mean corpuscular volume	7.000000e-11
GCST90002403_466	Red blood cell count	3.000000e-24

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0004305	erythrocyte count
EFO:0004340	body mass index
EFO:0006335	systolic blood pressure
EFO:0004530	triglyceride measurement
EFO:0004531	urate measurement
EFO:0000266	aortic stenosis
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004348	hematocrit
EFO:0004509	hemoglobin measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D013577	Syndrome	C23.550.288.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, decreases expression, increases methylation	3
bisphenol F	decreases methylation, increases expression	2
Benzo(a)pyrene	affects methylation, decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
TAK-243	increases sumoylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation, affects cotreatment, increases methylation	1
trichostatin A	increases expression	1
arsenite	affects binding, decreases reaction	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
bisphenol S	affects methylation	1
Resveratrol	decreases expression, affects cotreatment	1
Fulvestrant	affects cotreatment, increases methylation	1
Air Pollutants	affects expression, increases abundance	1
Arsenic	affects methylation	1
Cisplatin	decreases expression	1
Estradiol	increases expression	1
Hydralazine	affects cotreatment, increases expression	1
Ozone	affects expression, increases abundance	1
Plant Extracts	affects cotreatment, decreases expression	1
Silicon Dioxide	decreases expression	1
Smoke	decreases expression	1
Thiram	increases expression	1
Tretinoin	decreases expression	1
Aflatoxin B1	increases methylation	1
Cadmium Chloride	increases expression	1

Clinical trials (associated diseases)

27 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00027456	PHASE2	COMPLETED	Leptin to Treat Severe Insulin Resistance - Pilot Study
NCT06310681	Not specified	COMPLETED	Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability
NCT07303049	Not specified	NOT_YET_RECRUITING	Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder
NCT00213447	Not specified	COMPLETED	T Cell Response in Hypersensitivity Syndrome
NCT02240888	Not specified	COMPLETED	Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
NCT02526082	Not specified	ACTIVE_NOT_RECRUITING	Long-term Follow-up of the Helsinki Businessmen Study
NCT02637518	Not specified	UNKNOWN	Comprehensive Validation of Frailty Assessment Tools in Older Adults in Different Clinical and Social Settings
NCT02971072	Not specified	COMPLETED	Neurophysiology of Weakness and Exercise in Rotator Cuff Tendinopathy
NCT02974569	Not specified	COMPLETED	Improving Symptom Self-management in Adolescents & Young Adults With Cancer
NCT03265561	Not specified	COMPLETED	Spinal Infection Management With Structural Allograft
NCT04190342	Not specified	COMPLETED	Effects of a Traditional Chinese Exercise Program on Symptom Cluster in Breast Cancer Patients
NCT04874584	Not specified	COMPLETED	Culturally Tailored Nurse Coaching Study for Cancer Symptom Management
NCT04909489	Not specified	UNKNOWN	PDR and SKYD of Dyslipidemia’s Characteristics From the Oxidative Stress Enhancement Caused by Inhibition of Serine Metabolic Pathway
NCT05218122	Not specified	UNKNOWN	Characteristics of LKDS and PBSS of KOA Based on the Enhancement of Inflammatory Response by TGF-β/Smad Pathway Inhibited
NCT05266118	Not specified	COMPLETED	Patient Reported Symptoms the First Week After Intensive Care Unit Discharge and up to Hospital Discharge
NCT05321966	Not specified	COMPLETED	The Effect of Video Training on Symptom Burden Patients Undergoing Hemodialysis Treatment
NCT05818748	Not specified	UNKNOWN	Effect Of Virtual Reality Distraction on Symptom Control and Anxiety in Children With Leukemia
NCT05837988	Not specified	UNKNOWN	Construction of Symptom Network in Maintenance Hemodialysis Patients
NCT06143436	Not specified	UNKNOWN	TCM Constitution, Pattern Types, and Disease Factors in Primary Lung Cancer.
NCT06222008	Not specified	UNKNOWN	Study on Symptom Clusters During Chemotherapy in Ovarian Cancer Patients With Different Chinese Medicine Constitution
NCT06412107	Not specified	COMPLETED	Somatic Acupressure for Symptom Cluster Management in Breast Cancer Survivors
NCT06847360	Not specified	RECRUITING	Home-based Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for IBS Pain
NCT07281300	Not specified	RECRUITING	Mindfulness-Oriented Respiratory Distress Symptom Intervention for Lung Cancer
NCT07315672	Not specified	RECRUITING	Acupressure for Cough in Lung Cancer Survivors
NCT07479654	Not specified	NOT_YET_RECRUITING	AI-Enabled Frailty Risk Prediction in Adult Congenital Heart Disease
NCT07495358	Not specified	NOT_YET_RECRUITING	Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cancer Undergoing Chemotherapy
NCT07576114	Not specified	RECRUITING	Comparison of Gluteal Muscle Activation and Core Strengthening in Dead Butt Syndrome Syndrome